The BioFIT 2017 conference programme is designed to address the needs of its audience constituted by academia, TTOs, research institutions, pharma, biotech companies, but also law experts and investors in pre-seed, seed and Series A. The BioFIT agenda aims to provide solutions, best practices for every player of the sector.

BioFIT’s 2017 wide-ranging programme has been redesigned around three tracks:

  • Track 1: New players involved in innovation in the health sector
  • Track 2: Nurturing and licensing early-stage assets
  • Track 3: Bioentrepreneurs’ challenges at pre-seed, seed and Series A stages

This year’s aim is to focus on bioentrepreneurship, explore the mutually beneficial relationships between academia and industry, address access to seed capital, and oversee new trends in financing early-stage innovation.

The event reflects the fast-paced and dynamic Life Sciences sector.


PLENARY SESSION


TRACK 1:
NEW PLAYERS INVOLVED IN INNOVATION IN THE HEALTH SECTOR

Big data and health IT companies provide key expertise to potentially increase efficiency in the discovery, preclinical and clinical stages of development. What will be their position and involvement in the therapeutic innovation chain: Will they participate or lead? Examples of collaborations between biotech, pharma and academic research will be highlighted. However, these new players don’t only originate from the big data sector, they also come from various areas such as animal health or e-health.


 TRACK 2:
NURTURING AND LICENSING EARLY-STAGE ASSETS

Early-stage assets evolve in an ecosystem in which TTOs, scientists and entrepreneurs are closely connected. This subject will focus on assessing opportunities in licensing early-stage projects, discussing the mentoring role of TTOs and exploring scientists’ commitment. It aims to underline the difficulties for maturing early-stage assets. How can we transform science into business more frequently and efficiently?


TRACK 3:
BIOENTREPRENEURS’ CHALLENGES AT PRE-SEED, SEED AND SERIES A STAGES

The right mindset, a solid presentation and business model are not the sole requirements that bioentrepreneurs must fulfil at pre-seed, seed and Series A stages. What are the expectations of project maturity from investors in 2017? How often are new types of early-stage investors involved in financing rounds (including philanthropic and specialised ventures)? How does the angels/seed investors relationship work? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?